Kieren Marr, MD, MBA is the medical director of the Transplant and Oncology Infectious Diseases Program and a professor of medicine and oncology at the Johns Hopkins University School of Medicine. Dr. Marr, a member of the Johns Hopkins Kimmel Cancer Center, trained at Hahnemann University, Duke University and the University of Washington / Fred Hutchinson Cancer Research Center, where she was on faculty for 13 years prior to relocation to Johns Hopkins in 2008. Dr. Marr is a member of several national and international professional organizations, numerous national scientific steering committees, has authored over 200 peer-reviewed publications and textbook chapters, and edited two books in the area of infectious diseases involving immunosuppressed hosts. She has been recognized as elected member of the honorary medical societies, the Association of American Physicians (AAP) the American Society for Clinical Investigators (ASCI), where she served on council and President (2015-2019), and Fellow of Infectious Diseases Society of America (IDSA). She is known worldwide for her translational and clinical research focused on diagnostics and treatment of invasive fungal infections. Her research led to establishment of a JHU spin-off company, MycoMed Technologies, focused on development of diagnostics to enable early treatment of fungal infections in medically immunosuppressed people. Dr. Marr earned an MBA at MIT Sloan School of Business and holds a co-appointment in the Johns Hopkins Carey School of Business. She has an active interest in healthcare innovation and entrepreneurship and serves as a Vice Chair in the Johns Hopkins Department of Medicine, focusing on Innovation in Healthcare Implementation.
